Current Clinical Trials in the Treatment of Advanced Melanomas

Sarkisian, Saro; Nair, Suresh; Sharma, Rohit

doi:10.1016/j.suc.2019.09.014

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are ongoing melanoma clinical trials in the USA, aiming to find new and improved treatment options for patients with advanced disease. An example of a multicenter phase III randomized controlled trial (RCT), which is actively recruiting patients, is "A Study of NKTR-214 Combined With Nivolumab vs. Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma" [9]. Although this patient would have been a good candidate for this trial based on her clinical diagnosis, she may not qualify based on her decreased performance status per the Eastern Cooperative Oncology Group (ECOG) scale of performance status used by many clinical trials as an inclusion criterion [10].…”

Section: Discussionmentioning

confidence: 99%

A Case of Diffuse Metastatic Melanoma With Massive Spontaneous Hemoperitoneum

Addae

Rawlinson

Adjei

et al. 2020

Cureus

View full text Add to dashboard Cite

The incidence rate for melanoma continues to rise in the USA. The majority of melanoma cases are detected at an early stage and are amenable to surgical excision. Advanced melanoma with diffuse intraabdominal metastasis is rare. We present a case of a 50-year-old female with no known primary or history of melanoma who presented with massive intraabdominal bleeding secondary to diffuse metastatic melanoma with peritoneal implants. Diagnosing metastatic melanoma could be challenging. Clinicians should be aware of hemoperitoneum or peritoneal carcinomatosis as potential manifestations of malignant melanoma to expedite appropriate management.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Diffuse Metastatic Melanoma With Massive Spontaneous Hemoperitoneum

Addae

Rawlinson

Adjei

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Melanoma cells have a high ability of local invasion and metastasis, even when arising from very small-volume tumors [45]. Once in advanced stages, the prognosis of melanoma is still poor, despite being the subject of intense research groups and numerous clinical trials that have increased therapeutic options, such as certain targeted and immunotherapies [46].…”

Section: Expression Of T-type Calcium Channels In Melanomamentioning

confidence: 99%

T-Type Calcium Channels: A Potential Novel Target in Melanoma

Barceló

Sisó

Maiques

et al. 2020

Cancers

View full text Add to dashboard Cite

T-type calcium channels (TTCCs) are overexpressed in several cancers. In this review, we summarize the recent advances and new insights into TTCC biology, tumor progression, and prognosis biomarker and therapeutic potential in the melanoma field. We describe a novel correlation between the Cav3.1 isoform and the increased basal autophagy in BRAF V600E -mutant melanomas and after acquired resistance to BRAF inhibitors. Indeed, TTCC blockers reduce melanoma cell viability and migration/invasion in vitro and tumor growth in mice xenografts in both BRAF-inhibitor-sensitive and -resistant scenarios. These studies open a new, promising therapeutic approach for disseminated melanoma and improved treatment in BRAFi relapsed melanomas, but further validation and clinical trials are needed for it to become a real therapeutic option.

show abstract

“…Conventional treatments, including chemotherapy and radiotherapy, are ineffective, with a 5-year survival of 5% (Dowling, et al 2019). Nevertheless, new expensive biological drugs (i.e., immunotherapy with checkpoint inhibitors) or targeted therapy (BRAF and MEK inhibitors) have been designed in recent years, which may prolong survival with a specific 5-year survival of 50% (Sarkisian, et al 2020). Currently, the average cost of diagnosis and treatment of MM is 10 times greater than that of nonmelanoma skin cancer (Karimkhani, et al 2017).…”

Section: Introductionmentioning

confidence: 99%